10-Q quarterly report · filed Nov 12, 2026

FENNEC PHARMACEUTICALS INC. (FENC) Q3 2026 10-Q Quarterly Report

Short answer

FENNEC PHARMACEUTICALS INC. (FENC) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $20M (up 57.3% year over year) with net income of $5M.

Q3 2026 key financials · XBRL

Revenue
$20M
+57.3% YoY · +9.7% QoQ
Net income
$5M
+828.4% YoY · +135.2% QoQ
Operating margin
23.7%
EPS (diluted)
$0.13
+750.0% YoY · +160.0% QoQ

Source: XBRL data from the FENNEC PHARMACEUTICALS INC. (FENC) Q3 2026 10-Q on SEC EDGAR. USD.

FENNEC PHARMACEUTICALS INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $19,608, up $7,146 YoY, including PEDMARK sales $19,425, up 56% from $12,462
  • Cost of product sales margin 4% vs 5% YoY, driven by manufacturing and inventory efficiencies
  • Best performer: PEDMARK product sales, $19,425, up $6,963 YoY; only commercial product disclosed
  • Cash $48,684 vs $36,788 at December 31, 2025; operating cash flow $9,111 vs $(6,511)
  • Outlook: Japan registration strategy and partnering discussions ongoing; additional European launches planned in 2026

Risk Factors

  • No material changes from 10-K risk factors disclosed this quarter
  • Carried-forward business risk: disclosed risks could impair future growth prospects
  • Carried-forward financial risk: disclosed risks could adversely affect financial condition
  • Carried-forward operating risk: disclosed risks could harm results of operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other FENNEC PHARMACEUTICALS INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.